Currently, lower ANXA2 expression in prostate cancer patients, compared to that in benign prostatic hyperplasia, correlates with an advanced clinical stage, more frequent recurrence, and regional lymph node and distant metastasis and may serve as a useful biomarker [73]. This evidence concerns the gene ANXA2 and Familial prostate cancer.